UniProtKB/Swiss-Prot Q99988: Variant p.Ser48Thr

Growth/differentiation factor 15
Gene: GDF15
Feedback?

Variant information Variant position:

48 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Serine (S) to Threonine (T) at position 48 (S48T, p.Ser48Thr). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from small size and polar (S) to medium size and polar (T) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Other resources:

Links to websites of interest for the variant.

Variant rs1059369 [ dbSNP | Ensembl ]

Sequence information Variant position:

48 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

308 The length of the canonical sequence.
Location on the sequence:

GALSLAEASRASFPGPSELH S EDSRFRELRKRYEDLLTRLR The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         GALSLAEASRASFPGPSELHSEDSRFRELRKRYEDLLTRLR

Mouse                         DALAMPEQRPS---GPESQLNAD----ELRGRFQDLLSRLH

Rat                           DALALPEQRRS---LSESQLNPD----ELRGRFQDLLSRLH

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Propeptide	30 – 194

Literature citations
Human cDNA encoding a novel TGF-beta superfamily protein highly expressed in placenta.
Yokoyama-Kobayashi M.; Saeki M.; Sekine S.; Kato S.;
J. Biochem. 122:622-626(1997)
Cited for: NUCLEOTIDE SEQUENCE [MRNA]; VARIANTS LEU-9 AND THR-48; TISSUE SPECIFICITY; MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily.
Bootcov M.R.; Bauskin A.R.; Valenzuela S.M.; Moore A.G.; Bansal M.; He X.Y.; Zhang H.P.; Donnellan M.; Mahler S.; Pryor K.; Walsh B.J.; Nicholson R.C.; Fairlie W.D.; Por S.B.; Robbins J.M.; Breit S.N.;
Proc. Natl. Acad. Sci. U.S.A. 94:11514-11519(1997)
Cited for: NUCLEOTIDE SEQUENCE [MRNA]; VARIANTS LEU-9 AND THR-48; Cloning of human full-length CDSs in BD Creator(TM) system donor vector.
Kalnine N.; Chen X.; Rolfs A.; Halleck A.; Hines L.; Eisenstein S.; Koundinya M.; Raphael J.; Moreira D.; Kelley T.; LaBaer J.; Lin Y.; Phelan M.; Farmer A.;
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]; VARIANTS LEU-9 AND THR-48;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.